MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Positive effect of Medical Cannabis in adults with Tourette syndrome

S. Anis, S. Arad, C. Zalomek, H. Shabtai, T. Taichman, N. Giladi, T. Gurevich (Tel Aviv, Israel)

Meeting: MDS Virtual Congress 2021

Abstract Number: 1326

Keywords: Tics(also see Gilles de la Tourette syndrome): Treatment

Category: Tics/Stereotypies

Objective: To assess the effect of Medical Cannabis (MC) on Tourette Syndrome (TS) tics and impairment.

Background: TS is a childhood onset neuropsychiatric disorder characterized by the presence of multiple motor and at least one phonic tic lasting more than one year. Several randomized controlled and retrospective trials demonstrated MC may suppress tics and associated behavioral problems. Interrelation of the endocannabinoid system in the cortico-striato-thalamo-cortical circuit, limbic system and insula all play a major role in the pathophysiology of TS may explain the observed mitigation of symptoms.

Method: An open label prospective study of patients from the TS clinic at the Tel-Aviv Sourasky Medical Center, with approved MC licensing from the ministry of health. Type of the MC and mode of use were recommended by the treating neurologist.  Overall follow-up period was 3 months. Patients were assessed at one and 3-month following treatment initiation for treatment efficacy, tolerability and side effects.

Results: 18 patients entered the study, age (mean± standard error) 31.11±2.17, 12 males. Baseline Yale Global Tic Severity Scale (YGTSS)-severity (range 0-50) 25.27±2.47, YGTSS-impairment (range 0-50) 35.00±2.58. Three patients did not reach end of follow up. Average dose of MC after 3 months (grams/month) 18.00±1.33, %THC 12.33±1.24, %CBD 3.61±0.83, mode of administration: cigarettes (80%), vapor (13%), oil (13%), frequency of use 2.93±0.34 (per day), response of tics to treatment (Likert scale 1-7) 5.5±0.35, percent subjective reduction of tics (0-100%) 53.93±6.78. Average reduction of YGTSS-total for naïve users after three months of treatment was 37.07%. Major side effects include dry mouth (66.67%), fatigue (53.33%) and dizziness (46.67%). Three patients suffered from anxiety at treatment initiation: one stopped treatment because of worsening of obsessive-compulsive disorder, one from panic attack which resolved after THC dose reduction and one from anxiety which resolved with no treatment modification. Five patients reported cognitive side effects regarding (one patient for each) time perception, visuospatial disorientation, confusion, slow processing speed and attention.

Conclusion: Preliminary results show that MC has good efficacy and good tolerability. The most common mode of use is smoking with a high THC percentage. Cognitive and psychiatric side effects have to be monitored and addressed.

To cite this abstract in AMA style:

S. Anis, S. Arad, C. Zalomek, H. Shabtai, T. Taichman, N. Giladi, T. Gurevich. Positive effect of Medical Cannabis in adults with Tourette syndrome [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/positive-effect-of-medical-cannabis-in-adults-with-tourette-syndrome/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/positive-effect-of-medical-cannabis-in-adults-with-tourette-syndrome/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley